Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB) Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified ...

the SHIMMER study in DLB and the SHINE study in Alzheimer’s disease. These results show the value that zervimesine holds as we advance towards Phase 3 clinical trials. Looking ahead, we will ...

from the Extension phase of the Phase 2b RewinD-LB study that show neflamapimod demonstrated a clinically meaningful effect on slowing clinical progression in patients with DLB in an oral presentation ...

MINOT,N.D.–The DLB-LC Lakers softball team put on a show at home, as they took down the New Town Eagles 22-0. Divide County ...

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter ...

A woman who will soon have her first child is frustrated with her sister, who recently gave birth and has become "obsessed" ...

See α-Synuclein. Candidate tracer SY08 detects α-synuclein deposits in the brainstem (right) and parietal cortex (left) of ...

conducted a study on the frequency of infarcts in cortical, subcortical, and infratentorial areas of AD and DLB patients in a control group. The results of Sarro et al.'s study show that the overall ...